Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Treatment of postmenopausal osteoporosis in a patient with celiac disease

Abstract

Background. A 62-year-old postmenopausal woman with a family history of breast cancer, mild gastroesophageal reflux disease, iron-deficient anemia and declining BMD was seen in a specialist center for the evaluation and management of osteoporosis.

Investigations. Analysis of tissue transglutaminase IgA, endoscopic biopsy, serial BMD scans, FRAX® calculation of osteoporotic fracture risk, Gail model calculation of breast cancer risk, assessment of blood vitamin D concentration and secondary evaluation for osteoporosis.

Diagnosis. Osteoporosis, persistent after 12 years of hormone replacement therapy, and celiac disease.

Management. The patient was initially treated for bone loss with postmenopausal hormone replacement therapy. DXA analyses showed a continued decline in BMD despite adequate replacement of calcium and vitamin D levels and withdrawal of gluten from the patient's diet. An oral bisphosphonate was recommended with plans to reassess BMD after 1 year.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Small bowel mucosa of the case patient.

References

  1. Cauley, J. A. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290, 1729–1738 (2003).

    Article  CAS  Google Scholar 

  2. Watts, N. B., Lewiecki, E. M., Miller, P. D. & Baim, S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J. Clin. Densitom. 11, 473–477 (2008).

    Article  Google Scholar 

  3. World Health Organization Collaborating Centre for Metabolic Bone Diseases WHO Fracture Risk Assessment Tool [online] (2009).

  4. National Osteoporosis Foundation [online] (2009).

  5. Gail, M. H. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879–1886 (1989).

    Article  CAS  Google Scholar 

  6. Rostom, A. et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology 128 (Suppl. 1) S38–S46 (2005).

    Article  Google Scholar 

  7. Rostom, A., Murray, J. A. & Kagnoff, M. F. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 131, 1981–2002 (2006).

    Article  Google Scholar 

  8. AGA Institute. AGA Institute medical position statement on the diagnosis and management of celiac disease. Gastroenterology 131, 1977–1980 (2006).

  9. US Department of Health and Human Services. National Institutes of Health Consensus Development Conference Statement [online], (2004).

  10. Niewinski, M. M. Advances in celiac disease and gluten-free diet. J. Am. Diet Assoc. 108, 661–672 (2008).

    Article  Google Scholar 

  11. Pietzak, M. M. Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology 128 (Suppl. 1), S135–S141 (2005).

    Article  Google Scholar 

  12. Chapuy, M. C. et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 7, 439–443 (1997).

    Article  CAS  Google Scholar 

  13. Olmos, M. et al. Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Dig. Liver Dis. 40, 46–53 (2008).

    Article  CAS  Google Scholar 

  14. Legroux-Gérot, I. et al. Screening for celiac disease in patients with osteoporosis. Joint Bone Spine 76, 162–165 (2009).

    Article  Google Scholar 

  15. Kavuncu, V., Dundar, U., Ciftci, I. H., Evcik, D. & Yigit, I. Is there any requirement for celiac disease screening routinely in postmenopausal women with osteoporosis? Rheumatol. Int. 29, 841–845 (2009).

    Article  CAS  Google Scholar 

  16. Yu, E. W. et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif. Tissue Int. 83, 251–259 (2008).

    Article  CAS  Google Scholar 

  17. Roux, C. et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif. Tissue Int. 84, 13–19 (2009).

    Article  CAS  Google Scholar 

  18. Mautalen, C. et al. Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients. Am. J. Gastroenterol. 92, 313–318 (1997).

    CAS  PubMed  Google Scholar 

  19. National Institute of Diabetes and Digestive and Kidney Diseases National Digestive Diseases Information Clearinghouse [online], (2009).

  20. Stenson, W. F., Newberry, R., Lorenz, R., Baldus, C. & Civitelli, R. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch. Intern. Med. 165, 393–399 (2005).

    Article  Google Scholar 

Download references

Acknowledgements

Written consent for publication was obtained from the patient. Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to JoAnn V. Pinkerton.

Ethics declarations

Competing interests

J. V. Pinkerton declares associations with the following companies: Amgen (consultant), Boehringer Ingelheim (consultant), Eli Lilly (consultant), NovoNordisk (consultant), Pfizer (grant/research support), Wyeth (consultant, grant/research support). The other authors, the Journal Editor V. Heath and the CME questions author C. P. Vega declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pinkerton, J., Dalkin, A., Crowe, S. et al. Treatment of postmenopausal osteoporosis in a patient with celiac disease. Nat Rev Endocrinol 6, 167–171 (2010). https://doi.org/10.1038/nrendo.2009.272

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2009.272

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing